SYGNIS introduces 2view unique Western blot detection technology

May 9th, 2018

Heidelberg, Germany and Cambridge, UK, 09 May 2018 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced the introduction of 2view™, a unique detection method optimised for Western blotting, under its Expedeon brand name. 2view™ is an innovative double labeled secondary antibody that enables extended detection within the widely used Western blot application….

View

Your preferred local currency is now